Zobrazeno 1 - 10
of 100
pro vyhledávání: '"R M Sharkey"'
Autor:
D M Goldenberg, R M Sharkey
Publikováno v:
Oncogene. 26:3734-3744
This article reviews the development of radioimmunoconjugates as a new class of cancer therapeutics. Numerous conjugates involving different antigen targets, antibody forms, radionuclides and methods of radiochemistry have been studied in the half-ce
Publikováno v:
Nuclear Medicine Communications. 18:142-148
LL1, a monoclonal antibody (MAb) to HLA Class-II-like antigen (li determinant) on the surface of B-lymphocytes, monocytes and histiocytes, was evaluated as an agent for bone marrow imaging. Six patients with diverse diseases (non-Hodgkin's lymphoma,
Autor:
R. M. Sharkey, William C. Eckelman, K. Ramalingam, David P. Nowotnik, K. E. Linder, Rama K. Narra, F. Yost, M. D. Wen, A. D. Nunn
Publikováno v:
Bioconjugate Chemistry. 2:407-414
BATO (boronic acid adduct of technetium dioximes) complexes, TcCl(dioxime)3BR, were prepared in which the boron substituent (R) was the protein-reactive 2-carboxy-4-phenyl isothiocyanate (CPITC). The 99Tc complexes, where the dioxime was either dimet
Autor:
D M, Goldenberg, R M, Sharkey
Publikováno v:
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of.... 50(4)
Two radiolabeled antibody products for the treatment of non-Hodgkin's lymphoma have been approved, thus indicating that cancer radioimmunotherapy (RAIT) has finally come of age as a new therapeutic modality, exemplifying the collaboration of multiple
Autor:
T M, Behr, R D, Blumenthal, S, Memtsoudis, R M, Sharkey, S, Gratz, W, Becker, D M, Goldenberg
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 6(12)
There is currently no method to cure patients with disseminated colorectal cancer, which is the third leading cancer killer in the Western World. This report shows that the GW-39 intrapulmonary micrometastatic human colonic cancer model in nude mice
Autor:
M E, Juweid, G, Hajjar, R, Stein, R M, Sharkey, T, Herskovic, L C, Swayne, S, Suleiman, M, Pereira, A D, Rubin, D M, Goldenberg
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 41(1)
This phase I study was initiated to determine the toxicity and therapeutic potential of high-dose 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen monoclonal antibody (MAb) combined with autologous hematopoietic stem cell rescue (AHSCR) in patients wi
Autor:
T M, Behr, G, Sgouros, M G, Stabin, M, Béhé, C, Angerstein, R D, Blumenthal, C, Apostolidis, R, Molinet, R M, Sharkey, L, Koch, D M, Goldenberg, W, Becker
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5
Usually, the red marrow (RM) is the first dose-limiting organ in radioimmunotherapy. However, several studies have obtained only poor correlations between the marrow doses and the resulting toxicities. Furthermore, RM doses are mostly not determined
Autor:
S O, Leung, Z, Qu, H J, Hansen, L B, Shih, J, Wang, M J, Losman, D M, Goldenberg, R M, Sharkey
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5
Antibody (Ab) fragments are preferred agents for imaging applications because of their rapid clearance from the blood, thereby providing high tumor:blood ratios within a few hours. Several preclinical studies have also suggested that Ab fragments mig
Autor:
T M, Behr, B, Wörmann, M, Gramatzki, J, Riggert, S, Gratz, M, Béhé, F, Griesinger, R M, Sharkey, H J, Kolb, W, Hiddemann, D M, Goldenberg, W, Becker
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5
Both CD22 and CD20 have been used successfully as target molecules for radioimmunotherapy (RAIT) of low-grade B cell non-Hodgkin's lymphoma. Because both CD20 and CD22 are highly expressed relatively early in the course of B cell maturation, and beca
Autor:
T M, Behr, A L, Salib, T, Liersch, M, Béhé, C, Angerstein, R D, Blumenthal, A, Fayyazi, R M, Sharkey, B, Ringe, H, Becker, B, Wörmann, W, Hiddemann, D M, Goldenberg, W, Becker
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5
At the time of surgery, occult metastases (micrometastases) are present in more than 50% of colorectal cancer patients, and the liver is the most frequent site of apparent metastatic disease. Frequently, adjuvant chemotherapy is unable to prevent tum